Bicara (BCAX) President Cohlhepp logs small 149-share sale under 10b5-1 plan

Rhea-AI Filing Summary

Bicara Therapeutics Inc. President and COO Ryan Cohlhepp, who also serves as a director, reported a small open-market sale of company stock. On January 15, 2026, he sold 149 shares of Common Stock at a price of $18.02 per share, coded as a sale transaction. After this trade, he beneficially owned 213,992 shares of Bicara Therapeutics Common Stock in direct ownership form. The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that was adopted on February 12, 2025, indicating it was pre-arranged under SEC rules.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohlhepp Ryan

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		S(1)		149	D	$18.02	213,992	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in this Bicara Therapeutics (BCAX) Form 4 filing?

The insider is Ryan Cohlhepp, who is both a director and the President and COO of Bicara Therapeutics Inc. (BCAX).

What transaction did Ryan Cohlhepp report in Bicara Therapeutics (BCAX) stock?

He reported a sale (transaction code S) of 149 shares of Common Stock of Bicara Therapeutics Inc.

At what price were the Bicara Therapeutics (BCAX) shares sold in this Form 4?

The 149 shares of Bicara Therapeutics Common Stock were sold at a price of $18.02 per share.

How many Bicara Therapeutics (BCAX) shares does Ryan Cohlhepp own after this transaction?

Following the reported sale, Ryan Cohlhepp beneficially owned 213,992 shares of Bicara Therapeutics Inc. Common Stock in direct ownership.

Was the Bicara Therapeutics (BCAX) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was executed under a Rule 10b5-1 trading plan that was adopted on February 12, 2025.

What is the ownership form of the Bicara Therapeutics (BCAX) shares held by Ryan Cohlhepp after the sale?

The 213,992 shares of Bicara Therapeutics Common Stock reported after the transaction are held in direct (D) ownership.